GeneSys Bio's portable AI system detects pathogens and AMR in < 30 mins with >98% sensitivity, replacing slow lab tests and saving lives.
GeneSys Bio has raised $107K in total funding. The most recent round was Grant. The last funding was announced in June 2024.
GeneSys Bio's investors include CDP Venture Capital, Berkeley SkyDeck Fund, Lazio Innova.
GeneSys Bio is headquartered in Montefiascone, Italy.
GeneSys Bio's portable AI system detects pathogens and AMR in < 30 mins with >98% sensitivity, replacing slow lab tests and saving lives.
GeneSys Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GeneSys Bio — Funding & Investors." VCBacked, June 25, 2024, https://www.vcbacked.co/company/genesys-bio. Accessed August 13, 2026.
VCBacked. (2024). GeneSys Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/genesys-bio
{{cite web |title=GeneSys Bio — Funding & Investors |url=https://www.vcbacked.co/company/genesys-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated